Care Rail

← Medical · Causes of death · how systems treat it

Interstitial lung disease

Respiratory · Master rank #34 · ~0.7% of deaths (Top 20 avg)

Short comparison of all 20 systems on one page. Click a country for the full treatment / prevention / lifestyle page.

Illustrative playbooks — composed from system archetype + cause pathway. Not clinical guidelines.
Japan#33 · 0.8%
Statutory insurance, fee schedule

High visit frequency, low unit prices, specialist access without US-style referral walls. Respiratory pathway via Statutory insurance, fee schedule.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Singapore#33 · 0.8%
S+3Ms (subsidy + MediSave + MediShield + MediFund)

Public clusters for most serious care; private ISP for those who pay up. Respiratory pathway via S+3Ms (subsidy + MediSave + MediShield + MediFund).

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Sweden#33 · 0.7%
Decentralized tax-funded

Primary-care centered; strong public health infrastructure. Respiratory pathway via Decentralized tax-funded.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Switzerland#33 · 0.8%
Mandatory private insurance

High spend, high access, canton variation. Respiratory pathway via Mandatory private insurance.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Netherlands#34 · 0.8%
Mandatory private insurance, regulated

Insurer-organized pathways; low uninsured rate. Respiratory pathway via Mandatory private insurance, regulated.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
South Korea#34 · 0.7%
NHI single payer + private hospitals

Very high utilization; hospital-heavy; aggressive screening culture. Respiratory pathway via NHI single payer + private hospitals.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Norway#34 · 0.8%
Tax-funded national system

Wealthy Nordic model; GP lists + municipal prevention. Respiratory pathway via Tax-funded national system.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
France#34 · 0.8%
Statutory health insurance

Ambulatory specialist access; strong pharma/device availability. Respiratory pathway via Statutory health insurance.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Taiwan#34 · 0.7%
NHI single payer

High ambulatory volume; global budgets constrain growth. Respiratory pathway via NHI single payer.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Denmark#34 · 0.8%
Tax-funded

Municipal prevention + regional hospitals. Respiratory pathway via Tax-funded.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Spain#34 · 0.8%
SNS tax-funded

Strong primary care; Mediterranean public-health framing. Respiratory pathway via SNS tax-funded.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Germany#34 · 0.7%
Statutory sickness funds

Ambulatory specialists + hospital sector; dense capacity. Respiratory pathway via Statutory sickness funds.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Israel#34 · 0.8%
Mandatory health funds

Fund-integrated care; strong tech/trauma capacity. Respiratory pathway via Mandatory health funds.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Finland#34 · 0.7%
Tax-funded / reforming

Public primary care + occupational health overlay. Respiratory pathway via Tax-funded / reforming.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Italy#34 · 0.8%
SSN tax-funded

GP gatekeeping; north/south performance gaps. Respiratory pathway via SSN tax-funded.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
United Kingdom#35 · 0.7%
NHS tax-funded

GP gatekeeping, NICE pathways, waiting-list rationing for elective care. Respiratory pathway via NHS tax-funded.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
New Zealand#35 · 0.7%
Tax-funded + private optional

Pharmac constrains drug spend; public hospitals for major care. Respiratory pathway via Tax-funded + private optional.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Canada#35 · 0.7%
Single payer (provincial)

Single-payer core with wait times; limited private parallel. Respiratory pathway via Single payer (provincial).

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
Australia#36 · 0.7%
Universal Medicare + private optional

Strong primary care gatekeeping with private hospital overflow. Respiratory pathway via Universal Medicare + private optional.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →
United States#36 · 0.7%
Medicare/Medicaid + commercial

High-tech acute care; prior auth; huge price variation by payer. Respiratory pathway via Medicare/Medicaid + commercial.

Treat Inhaled bronchodilators / steroids per phenotype
Prevent Tobacco control; clean air / occupational dust rules
Lifestyle Smoking cessation is the dominant lever
Full page →